Cel Cancer is one of the most lethal and prevalent diseases affecting people from all ages worldwide. Despite its harmful side effects, chemotherapy is still the main course of treatment in most of the cancer types, and the success of the therapy highly depends on the early diagnosis, i.e. before metastatic progression. One of the major factors affecting the success of chemotherapy is the development of multidrug resistance (MDR), where the cancer cells become resistant to chemotherapeutic agents with distinct structures.The objective of this innovation project is to develop the first clinical device (tagMDR) for the identification of MDR prior to or during cancer treatment. Being a low cost and easy-to-operate in vitro diagnostic (IVD) device, tagMDR will provide rapid and accurate discrimination and quantification of resistant cancer cells via a label-free and target specific isolation technology. This novel system will guide the medical oncologists for picking the most effective treatment strategy in a timely manner, avoiding the deleterious side effects of inappropriate chemotherapy and the associated costs. The unique selling points of tagMDR will be the cheaper, shorter, more predictable, and more successful chemotherapy treatments, and hence yielding happier people.An initial market study has already been carried out for determining the potential customers and partners for structuring the general framework of the business plan. This study will be detailed in Phase 1, and the potential collaborators for clinical tests and marketing will be investigated, following the market potential assessment and the cost analysis of tagMDR. Meantime, the procedures for CE and IDE certifications and the suitable sterilization methods will also be identified. The major outcome of the feasibility study will be an elaborated business plan for the next 10 years, to enable accurate positioning of tagMDR in IVD and microfluidics markets. Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidicsengineering and technologyother engineering and technologiesmicrotechnologylab on a chipmedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator MIKRO BIYOSISTEMLER ELEKTRONIK SANAYI VE TICARET ANONIM SIRKETI Wkład UE netto € 50 000,00 Adres MUSTAFA KEMAL MAH DUMLUPINAR BLV ODTU TEKNOKENT ME YERLESKESI NO 280 B BLOK OFIS 10 06530 CANKAYA ANKARA Turcja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Batı Anadolu Ankara Ankara Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
